Dietary Nitrate Supplements and Ischemic Stroke Recovery


Phase 2 Results

Eligibility Criteria

Inclusion Criteria

- Patients 18 years old and over
- Diagnosed with an ischemic stroke (acute focal neurological deficit resulting from an ischemic cause, verified by CT or MRI)
- Symptom onset within 5 days of admission
- National Institutes of Health Stroke Scale Score of 2 or more (but less than 20)
- A rating of fair or good on static sitting balance scale on a global balance scale
- A score of more that 0 on the hip flexion on the short Fugl-Myer
- Passed dysphagia screening for unrestricted or thickened liquids

Exclusion Criteria

- Patients with severe stroke (National Institutes of Health Stroke Scale Score of 20 or more)
- A score of 0 on hip flexion on the Short Fugl-Myer as a result of weakness from the stroke
- A rating of poor on static sitting balance scale on a global balance scale
- Patients who received intravenous or intra-arterial recombinant tissue plasminogen activator (rtPA)
- Patients who are receiving citicoline
- Patients who have had a hemorrhagic stroke (including intraparenchymal, subarachnoid or subdural hemorrhage)
- A gait speed of more > 0.8 m/s
- Patient with evidence of brain tumor or other psychiatric or neurological condition that would interfere with outcome measures
- Patients who will undergo carotid endarterectomy or other surgery during the study period
- Patients not living independently prior to stroke
- Survival is expected to be less than 6 months
- Any patient on organic nitrate-containing medications; some examples of the medications that are exclusions include nitroglycerin, isosorbide mononitrate, sildenafil (Viagra), and tadalafil (Cialis)
- Patients with atrophic gastritis
- Patients with hypotension (blood pressure less than 100/60 mmHg)
- Patients who do not pass the dysphagia screening test